Holen Sie sich die Stockscreener-App
13.66
8.81%
-1.32
Handel nachbörslich:
13.66
Schlusskurs vom Vortag:
$14.98
Offen:
$13.72
24-Stunden-Volumen:
8.15M
Relative Volume:
1.53
Marktkapitalisierung:
$10.90B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.21B
KGV:
-8.5167
EPS:
-1.6039
Netto-Cashflow:
$-387.48M
1W Leistung:
-1.09%
1M Leistung:
-4.14%
6M Leistung:
-17.16%
1J Leistung:
-50.45%
1-Tages-Spanne:
$13.20
$14.42
1-Wochen-Bereich:
$13.20
$15.71
52-Wochen-Spanne:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
13.66 | 10.90B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating After Q2 Report - GuruFocus
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 - BioSpace
Guggenheim lowers Summit Therapeutics stock price target on trial timing By Investing.com - Investing.com Canada
Summit Therapeutics Signs Distribution Agreement With J.P. Morgan Securities for Common Stock Offering - Minichart
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Marke - Benzinga
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Yahoo Finance
Summit (SMMT) Completes Enrollment in Global HARMONi-3 Study - GuruFocus
Summit Therapeutics (SMMT) Reports Q2 EPS Beat with Strong Cash Position - GuruFocus
Summit Q2 2026 slides: ivonescimab OS data strengthens amid spending rise - Investing.com Nigeria
Summit Therapeutics (SMMT) Faces Financial Uncertainty Amid Funding Challenges - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Clinical Developments and Strong Cash Position - GuruFocus
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Summit Therapeutics Launches $380 Million At-the-Market Equity Offering Program with J.P. Morgan Securities - Kalkine Media
Summit Therapeutics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Summit Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Summit (SMMT) Advances Clinical Trials with Promising Ivonescima - GuruFocus
Concerns Rise for Summit Therapeutics (SMMT) Regarding Financial Viability - GuruFocus
Summit Therapeutics (SMMT) Faces Funding Challenges Amid Q2 Losses - GuruFocus
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain? - Yahoo Finance
SMMT Q2 FY2026 earnings call - finance.biggo.com
[SMMT Q2 2026 Earnings Call] Summit Therapeutics Cash Hits $690.7M, Updated HARMONi Data Shows HR 0.76 Overall Survival Ahead of PDUFA - finance.biggo.com
Summit Therapeutics Initiates $380 Million At-The-Market Stock Offering with J.P. Morgan - Kalkine Media
Earnings call transcript: Summit Therapeutics Q2 2026 loss widens as shares fall after hours - Investing.com Canada
SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Summit Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SMMT) 2026-07-23 - Seeking Alpha
Summit Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
Transcript : Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
Summit Therapeutics says cash crunch could impact its ability to continue - Seeking Alpha
Summit Therapeutics (SMMT) Q2 2026 earnings summary - Quartr
Summit Therapeutics Reports Ivonescimab Progress and Strong Cash - TipRanks
Summit Therapeutics (SMMT) sets up $380M at-the-market share offering - Stock Titan
Summit Therapeutics: substantial doubt about our ability to continue as a going concern - StreetInsider
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.19 per Share, vs. FactSet Est of $-0.17 - marketscreener.com
Summit Therapeutics (NASDAQ: SMMT) posts loss, eyes FDA decision - Stock Titan
Summit Therapeutics posts Q2 loss, reports ivonescimab trial data - StreetInsider
SMMT Reiterated by HC Wainwright & Co. -- Rating Maintained at N - GuruFocus
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study - Yahoo Finance
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics By Investing.com - Investing.com Nigeria
Why (SMMT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
0.46%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):